JP7849310B2 - 長時間作用性ｇｌｐ－１／ｇｉｐデュアルアゴニスト - Google Patents

長時間作用性ｇｌｐ－１／ｇｉｐデュアルアゴニスト

Info

Publication number
JP7849310B2
JP7849310B2 JP2022578936A JP2022578936A JP7849310B2 JP 7849310 B2 JP7849310 B2 JP 7849310B2 JP 2022578936 A JP2022578936 A JP 2022578936A JP 2022578936 A JP2022578936 A JP 2022578936A JP 7849310 B2 JP7849310 B2 JP 7849310B2
Authority
JP
Japan
Prior art keywords
ser
tbu
group
ala
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022578936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530515A5 (https=
JP2023530515A (ja
Inventor
セナティ，ラジャマンナル
ブラデ，ヴィノド・サンパタラオ
ナタラジャン，ムスクマラン
ジョシ，ディレン・ラメシュチャンドラ
ガンディー，マニシュ・ハレンドラプラサド
ジヴァニ，チャンドゥーラル・サカールシバーイー
ティワリ，アビセーク
ソニ，クルーナル・ハリシュバーイー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of JP2023530515A publication Critical patent/JP2023530515A/ja
Publication of JP2023530515A5 publication Critical patent/JP2023530515A5/ja
Application granted granted Critical
Publication of JP7849310B2 publication Critical patent/JP7849310B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2022578936A 2020-06-22 2021-06-21 長時間作用性ｇｌｐ－１／ｇｉｐデュアルアゴニスト Active JP7849310B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN202021026360 2020-06-22
IN202021026360 2020-06-22
IN202121002838 2021-01-20
IN202121002838 2021-01-20
PCT/IB2021/055457 WO2021260530A1 (en) 2020-06-22 2021-06-21 Long acting glp-1/gip dual agonists

Publications (3)

Publication Number Publication Date
JP2023530515A JP2023530515A (ja) 2023-07-18
JP2023530515A5 JP2023530515A5 (https=) 2024-06-26
JP7849310B2 true JP7849310B2 (ja) 2026-04-21

Family

ID=76891103

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022578936A Active JP7849310B2 (ja) 2020-06-22 2021-06-21 長時間作用性ｇｌｐ－１／ｇｉｐデュアルアゴニスト

Country Status (18)

Country Link
US (2) US20230241178A1 (https=)
EP (1) EP4146248A1 (https=)
JP (1) JP7849310B2 (https=)
KR (1) KR20230023658A (https=)
CN (1) CN115768460A (https=)
AU (1) AU2021296376A1 (https=)
BR (1) BR112022025615A2 (https=)
CA (1) CA3183358A1 (https=)
CL (1) CL2022003654A1 (https=)
CO (1) CO2022018464A2 (https=)
EC (1) ECSP22095556A (https=)
IL (1) IL299195A (https=)
JO (1) JOP20220344A1 (https=)
MX (1) MX2022016032A (https=)
PE (1) PE20230861A1 (https=)
PH (1) PH12022553526A1 (https=)
TW (1) TW202216746A (https=)
WO (1) WO2021260530A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20231309A1 (es) * 2020-10-17 2023-08-24 Sun Pharmaceutical Ind Ltd Agonistas duales glp-1/gip
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
US12281149B2 (en) 2021-05-13 2025-04-22 Carmot Therapeutics, Inc. Modulators of G-protein coupled receptors
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
WO2024098718A1 (zh) * 2022-11-07 2024-05-16 内蒙古博睿精创科技有限公司 一种新型长效多肽化合物、组合物及其应用
CN120865433A (zh) * 2022-12-21 2025-10-31 勃林格殷格翰国际有限公司 Glp1/gip/npy2受体的三重激动剂
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
KR20260022948A (ko) 2023-06-09 2026-02-20 썬 파마슈티컬 인더스트리스 리미티드 Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025163615A1 (en) 2024-01-31 2025-08-07 Sun Pharmaceutical Industries Ltd. High level production of glp1 analogues
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518115A (ja) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
JP2015517459A (ja) 2012-05-03 2015-06-22 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
JP2016540741A (ja) 2013-11-06 2016-12-28 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
JP2017507124A (ja) 2015-01-09 2017-03-16 イーライ リリー アンド カンパニー Ｇｉｐおよびｇｌｐ−１コアゴニスト化合物
WO2020023386A1 (en) 2018-07-23 2020-01-30 Eli Lilly And Company Gip/glp1 co-agonist compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
MX2020010505A (es) * 2018-04-05 2021-01-15 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1.
CN119499352A (zh) 2018-07-23 2025-02-25 伊莱利利公司 使用gip/glp1共激动剂用于糖尿病的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518115A (ja) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
JP2015517459A (ja) 2012-05-03 2015-06-22 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
JP2016540741A (ja) 2013-11-06 2016-12-28 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
JP2017507124A (ja) 2015-01-09 2017-03-16 イーライ リリー アンド カンパニー Ｇｉｐおよびｇｌｐ−１コアゴニスト化合物
WO2020023386A1 (en) 2018-07-23 2020-01-30 Eli Lilly And Company Gip/glp1 co-agonist compounds

Also Published As

Publication number Publication date
EP4146248A1 (en) 2023-03-15
MX2022016032A (es) 2023-04-19
US20230241178A1 (en) 2023-08-03
CO2022018464A2 (es) 2023-03-17
AU2021296376A1 (en) 2022-12-08
US20240424063A1 (en) 2024-12-26
PH12022553526A1 (en) 2024-01-22
CA3183358A1 (en) 2021-12-30
WO2021260530A1 (en) 2021-12-30
CN115768460A (zh) 2023-03-07
KR20230023658A (ko) 2023-02-17
JP2023530515A (ja) 2023-07-18
TW202216746A (zh) 2022-05-01
BR112022025615A2 (pt) 2023-01-17
JOP20220344A1 (ar) 2022-12-20
AU2021296376A8 (en) 2022-12-22
CL2022003654A1 (es) 2023-08-04
IL299195A (en) 2023-02-01
PE20230861A1 (es) 2023-05-30
ECSP22095556A (es) 2023-01-31

Similar Documents

Publication Publication Date Title
JP7849310B2 (ja) 長時間作用性ｇｌｐ－１／ｇｉｐデュアルアゴニスト
JP7830441B2 (ja) Ｇｌｐ－１／ｇｉｐ二重アゴニスト
KR102801994B1 (ko) 신규한 glp-1 유사체
CN103200966B (zh) 具有接头的双-酰化的glp-1衍生物
JP6297969B2 (ja) 部位特異的モノｐｅｇ化エキセンジン類似体およびその調製方法
CN104411322B (zh) 双酰化glp‑1衍生物
CN107108714A (zh) Glp‑1衍生物及其用途
US20070244041A1 (en) Peptide Yy Analogues
JP2013542211A (ja) グルコース依存性インスリン分泌促進ペプチド類似体
WO2020143625A1 (zh) 新型多肽及其治疗用途
RU2557301C2 (ru) Новые аналоги глюкагон-подобного пептида, композиция и способ применения
JP2025508820A (ja) Ｃｒｆ２受容体アゴニスト及び治療法におけるそれらの使用
EP1908778A1 (en) Exendin 4 polypeptide fragments and use thereof
EP4638481A1 (en) Glp1/gip/npy2 receptor triple agonists
CN115873096A (zh) 一种胰高血糖素糖肽-1和胰高血糖素受体双重激动多肽及其应用
EA053025B1 (ru) Двойные агонисты glp-1/gip
KR20250177378A (ko) Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 심혈관계 질환 예방 또는 치료용 약학적 조성물
CN119488582A (zh) 一种glp-1和pyy孪药及其制备方法和应用
WO2025257294A1 (en) Soluble glp1/gip/npy2 receptor triple agonists
KR20260022948A (ko) Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260409

R150 Certificate of patent or registration of utility model

Ref document number: 7849310

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150